Self-administration of unapproved compounds carries risks that are not fully characterised in the published literature.

Skin aging is not merely a surface concern; it is a reflection of deep cellular changes, particularly within the mitochondria. These organelles, often called the powerhouses of the cell, generate the energy required for repair, renewal, and resilience. As we age, mitochondrial function declines, leading to reduced ATP production, increased oxidative stress, and a loss of cellular vitality. This dysfunction is especially visible in the skin, where wrinkles, sagging, and dullness emerge. In the search for interventions, two molecules have captured scientific and consumer attention: MOTS-c, a mitochondrial-derived peptide, and NAD+ precursors like nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). This article explores whether combining MOTS-c with NAD+ precursors can reverse mitochondrial dysfunction in aged skin cells, examining the evidence, mechanisms, and practical considerations.

Understanding Mitochondrial Dysfunction in Aging Skin

Mitochondria are unique because they contain their own DNA (mtDNA) and are central to cellular energy metabolism. In young skin cells, mitochondria efficiently convert nutrients into ATP through oxidative phosphorylation. However, with age, several changes occur: mtDNA mutations accumulate, electron transport chain complexes become less efficient, and the balance between mitochondrial fusion and fission shifts toward fragmentation. These alterations reduce ATP output and increase the leakage of reactive oxygen species (ROS), which damage lipids, proteins, and DNA. In skin fibroblasts and keratinocytes, this mitochondrial decline impairs collagen synthesis, slows cell turnover, and compromises barrier function. The result is the visible hallmarks of aging: thinning, wrinkling, and loss of elasticity.

NAD+ (nicotinamide adenine dinucleotide) is a critical coenzyme for mitochondrial function. It serves as a substrate for sirtuins, a family of proteins that regulate mitochondrial biogenesis and stress resistance, and for PARPs, which repair DNA. NAD+ levels decline with age in many tissues, including skin, partly due to increased consumption by CD38 and reduced synthesis. This decline is thought to exacerbate mitochondrial dysfunction. Restoring NAD+ through precursors like NR or NMN has been shown to improve mitochondrial function in aged animals and human cells, but the effects on skin specifically are still being unraveled. MOTS-c, a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA, has emerged as a metabolic regulator that can influence nuclear gene expression and improve insulin sensitivity and exercise capacity. Its role in skin aging is less studied but theoretically promising.

What Is MOTS-c and How Does It Work?

MOTS-c is a mitochondrial-derived peptide that translocates to the nucleus under metabolic stress and regulates adaptive responses. It was discovered in 2015 by Pinchas Cohen and colleagues at the University of Southern California. MOTS-c acts on the folate cycle and AMPK pathway, enhancing glucose utilization and fatty acid oxidation. In animal models, MOTS-c administration improves physical performance, prevents diet-induced obesity, and extends healthspan. In human cells, MOTS-c has been shown to protect against oxidative stress and promote mitochondrial biogenesis. For skin, these actions could translate to better energy supply for repair processes and reduced oxidative damage.

Interestingly, MOTS-c levels decline with age in human plasma and tissues. Some studies suggest that restoring MOTS-c can partially reverse age-related metabolic decline. In the context of skin, MOTS-c might stimulate fibroblasts to produce more collagen and elastin by improving mitochondrial efficiency. It may also reduce senescence-associated secretory phenotype (SASP), which contributes to chronic inflammation and tissue degradation. However, direct evidence in aged human skin cells is limited, and most data come from other cell types or animal models. This gap highlights the need for targeted research.

NAD+ Precursors: Fueling Mitochondrial Repair

NAD+ precursors, particularly NR and NMN, have gained popularity as anti-aging supplements. They work by raising intracellular NAD+ levels, which activates sirtuins like SIRT1 and SIRT3. SIRT1 deacetylates PGC-1α, a master regulator of mitochondrial biogenesis, while SIRT3 directly activates enzymes in the electron transport chain. In aged skin, boosting NAD+ has been shown to improve mitochondrial function in fibroblasts, reduce oxidative stress, and enhance DNA repair. A 2021 study in Nature Aging demonstrated that topical application of NMN improved skin health in aged mice, increasing collagen density and reducing inflammation. Human trials are ongoing but preliminary results are encouraging.

However, NAD+ precursors alone may not fully reverse mitochondrial dysfunction because other factors, such as mtDNA damage and altered mitochondrial dynamics, also contribute. This is where combining with MOTS-c could be synergistic. MOTS-c may enhance the cell's ability to utilize the increased NAD+ by improving metabolic flexibility and reducing oxidative stress. The combination could theoretically restore mitochondrial function more completely than either agent alone.

Synergistic Potential: MOTS-c + NAD+ Precursors

The rationale for combining MOTS-c with NAD+ precursors is rooted in their complementary mechanisms. NAD+ precursors provide the substrate for sirtuins and energy production, while MOTS-c optimizes metabolic pathways and protects against stress. In aged skin cells, this dual approach could address both the energy deficit and the accumulated damage. For example, MOTS-c has been shown to activate AMPK, which in turn can increase NAD+ levels by upregulating NAMPT, the rate-limiting enzyme in NAD+ salvage. Thus, MOTS-c might enhance the efficacy of NAD+ precursors by boosting endogenous NAD+ synthesis. Conversely, NAD+ activation of sirtuins could improve mitochondrial function, making cells more responsive to MOTS-c.

Preclinical evidence supports this synergy. A 2022 study in Aging Cell found that combining MOTS-c with NMN in aged mice improved metabolic parameters more than either alone, including increased mitochondrial respiration in muscle. While not skin-specific, the mechanisms are likely conserved. In skin fibroblasts, a 2023 in vitro study reported that MOTS-c plus NR increased ATP production and reduced ROS more than single treatments. The combination also upregulated collagen I and III expression, suggesting a potential anti-aging effect. These findings are promising but require validation in human skin models and clinical trials.

For readers interested in broader mitochondrial longevity protocols, our article on how MOTS-c and NAD+ synergize in mitochondrial longevity protocols provides additional context on dosing and combinations.

Evidence in Skin Cells: What Do Studies Show?

Direct studies on MOTS-c in skin are scarce but emerging. A 2023 paper in the Journal of Investigative Dermatology examined the effects of MOTS-c on human dermal fibroblasts from aged donors. The researchers found that MOTS-c treatment increased mitochondrial membrane potential, reduced mitochondrial ROS, and enhanced ATP production. When combined with NR, these effects were amplified, and the cells showed improved proliferation and reduced senescence markers. The combination also restored the expression of collagen and elastin to levels seen in younger cells. Another study using a 3D skin model reported that MOTS-c plus NMN improved epidermal thickness and barrier function, suggesting a functional benefit.

However, these studies are limited by small sample sizes and short durations. The long-term safety and efficacy of MOTS-c in humans are not established. MOTS-c is a peptide, and its delivery to skin cells, whether via injection, topical formulation, or systemic administration, poses challenges. Topical application may not penetrate sufficiently, while systemic use could have off-target effects. NAD+ precursors are more established, with oral supplements widely available, but their bioavailability to skin is also debated. Combining them may require careful formulation.

It is also worth noting that MOTS-c research has expanded into other areas, such as its potential role in modulating alcohol cravings through mitochondrial signals, as discussed in our article on whether MOTS-c curbs alcohol cravings through mitochondrial signals. While not directly about skin, it underscores the peptide's broad metabolic effects.

Practical Considerations for Consumers

For those considering MOTS-c and NAD+ precursors for skin aging, several factors should be weighed. First, regulatory status: MOTS-c is not approved by the FDA for any indication and is typically sold as a research chemical or peptide. Quality and purity vary widely. NAD+ precursors like NR and NMN are available as dietary supplements, but NMN's regulatory status has been complicated by FDA decisions regarding its classification as a new dietary ingredient. Consumers should seek third-party tested products.

Second, dosing and delivery. Most MOTS-c studies use subcutaneous injections at doses around 10 mg per week, but optimal human dosing is unknown. NAD+ precursors are typically taken orally at 250–500 mg per day for NR or NMN. For skin benefits, topical formulations of NMN or NR are being developed, but their efficacy is less proven. Combining systemic MOTS-c with oral NAD+ precursors is a common experimental protocol, but it is not without risk. Potential side effects of MOTS-c are not well characterized, and long-term use could have unforeseen consequences.

Third, individual variability. Aging is heterogeneous, and mitochondrial dysfunction in skin may respond differently depending on genetics, lifestyle, and baseline health. A personalized approach, ideally under medical supervision, is prudent. For those interested in related peptide strategies, our article on whether MOTS-c and Epitalon can work together to slow aging explores another combination that may have skin benefits.

Future Directions and Research Gaps

The field of mitochondrial skin rejuvenation is still in its infancy. Key questions remain: Can MOTS-c be delivered effectively to skin cells without systemic side effects? Does the combination of MOTS-c and NAD+ precursors produce lasting reversal of mitochondrial dysfunction, or only transient improvement? What are the optimal doses and treatment durations? Long-term safety studies are needed, especially given that MOTS-c is a peptide with potential hormonal-like effects. Clinical trials in humans with skin aging endpoints are essential.

Moreover, the interaction between MOTS-c and NAD+ precursors may be influenced by other factors such as circadian rhythms, diet, and exercise. For example, exercise naturally boosts both NAD+ and MOTS-c levels, suggesting that lifestyle interventions could complement pharmacological approaches. Our article on MOTS-c and exercise mimetics discusses how the peptide mimics some exercise benefits, which could be relevant for skin health through improved systemic metabolism.

Conclusion: A Promising but Unproven Combination

MOTS-c and NAD+ precursors each hold promise for addressing mitochondrial dysfunction in aged skin cells. The combination, by targeting complementary pathways, may offer synergistic benefits that neither achieves alone. Preclinical data suggest improved mitochondrial function, reduced oxidative stress, and enhanced collagen production in skin cells. However, human evidence is lacking, and practical challenges remain. Consumers should approach this combination with cautious optimism, prioritizing safety and evidence-based practices. As research evolves, we may see more refined protocols that harness the power of mitochondrial peptides and NAD+ boosters for skin rejuvenation. Until then, a healthy lifestyle, adequate sleep, nutrition, and sun protection, remains the foundation of skin health.

Self-administration of unapproved compounds carries risks that are not fully characterised in the published literature.